The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients admitted with STEMI Treated by Primary Percutaneous Coronary Intervention A randomized controlled pilot trial - Effect of IV Cangrelor vs PO Ticagrelor on myocardial damage in STEMI

The Royal Wolverhampton NHS Trust0 个研究点目标入组 100 人开始时间: 2016年2月17日最近更新: 2020年7月20日

适应症

试验速览

暂无简介。

•1)Patients presenting with STEMI eligible for PPCI
•2)Able to give verbal assent pre procedure and written consent following the procedure.
•3)Age =18 years
•4)No contraindication to Cangrelor or Ticagrelor
•5)Thienopyridine naïve
•If a patient gives verbal assent but is unable to provide a written consent at a later stage due to incapacitation, presumed consent will be continued. The reasons why a patient becomes incapacitated and becomes unable to provide a written consent will be recorded during data collection.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

•1)Be unable to provide verbal assent and written consent
•2)Allergic to Aspirin or any of the P2Y12 antagonists in the trial
•3)Have pre-existing cardiogenic shock
•4)Previous myocardial infarction
•5)Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, and pneumonia.
•6)Already taking a P2Y12 inhibitor
•7)Known bleeding diathesis
•8)Significant active bleeding
•9)History of intracranial hemorrhage
•10)Patients who are being treated with formal anticoagulation (Vitamin K antagonist, Factor II or Xa inhibitors) or have an indication for anticoagulation during the first four hours of the study period. Example is patients known to have atrial fibrillation, pulmonary embolism or deep vein thrombosis.
•11)Known severe renal dysfunction requiring renal replacement therapy.

发起方